News and Events
Abexxa Biologics – Re-Imagining Cancer Immunotherapy for the many.
Jon Weidanz, CSO, talks about re-imaging cancer immunotherapy and the essential ingredients for successful partnerships
Abexxa Biologics has been selected as one of the 40 Best University Startups 2017
AbeXXa Biologics, a faculty startup at The University of Texas at Arlington, was named one of the 40 “Best University Startups 2017” by the National Council of Entrepreneurial Tech Transfer, a Washington-based association of startup officers from the top research universities in the United States.
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017
AbeXXa is looking to identify a new series of selective molecular targets for cancer from the many thousands of proteins found on the interior of a tumor cell.
Star-Telegram UTA raises cancer research profile with $6 million in grants
“It drives the success of the local economies in those areas,” said Weidanz, whose research focus is on an emerging field of therapies and treatments aimed at using a patient’s immune system to fight cancer. UTA recruited him partly for his experience starting research companies.
Abexxa Biologics won the Annual Innovation prize from #BIAcademy for their immunotherapy research & earned a Golden Ticket to Lab Central.
Abexxa Biologics wins space in lab central in Cambridge Massachusetts.
“Abexxa will focus on exploiting its novel targets for the development of next generation anti-cancer agents. “
© Copyright Abexxa Biologics, Inc. All Rights Reserved.